Ligand-Free, Copper-Catalyzed Ullmann-Type C–N Coupling: Regioselective Synthesis of Azole-Substituted Imidazo[1,2-a]pyridines

Pinku Kaswan; Kasiviswanadharaju Pericherla; Anil Kumar

doi:10.1055/s-0033-1339927

Synlett, Inhaltsverzeichnis

Synlett 2013; 24(20): 2751-2757
DOI: 10.1055/s-0033-1339927

letter

Ligand-Free, Copper-Catalyzed Ullmann-Type C–N Coupling: Regioselective Synthesis of Azole-Substituted Imidazo[1,2-a]pyridines

Pinku Kaswan

Department of Chemistry, Birla Institute of Technology and Science, Pilani 333031, India Fax: +91(1596)244183 eMail: anilkumar@pilani.bits-pilani.ac.in

,

Kasiviswanadharaju Pericherla

Department of Chemistry, Birla Institute of Technology and Science, Pilani 333031, India Fax: +91(1596)244183 eMail: anilkumar@pilani.bits-pilani.ac.in

,

Anil Kumar*

Department of Chemistry, Birla Institute of Technology and Science, Pilani 333031, India Fax: +91(1596)244183 eMail: anilkumar@pilani.bits-pilani.ac.in

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Abstract

A simple and highly efficient protocol for the regioselective synthesis of azole-substituted imidazo[1,2-a]pyridines has been developed using a ligand-free, copper-catalyzed Ullmann-type C–N coupling of 2-(2-bromophenyl)imidazo[1,2-a]pyridines with different azoles and in situ generated 1,2,3-triazoles. The reactions proceeded smoothly to furnish azolo-imidazo[1,2-a]pyridines in good to excellent yields (65–96%).

Key words

copper - ligand-free C–N coupling - imidazo[1,2-a]pyridines - 1,2,3-triazole - CuAAC - tandem reaction

Volltext

Referenzen

References and Notes

1a Ullmann F. Ber. Dtsch. Chem. Ges. 1903; 36: 2382
1b Ullmann F. Ber. Dtsch. Chem. Ges. 1904; 37: 853

2a Beletskaya IP, Cheprakov AV. Coord. Chem. Rev. 2004; 248: 2337
2b Liu Y, Wan J.-P. Org. Biomol. Chem. 2011; 9: 6873
2c Monnier F, Taillefer M. Angew. Chem. Int. Ed. 2009; 48: 6954

3a Klapars A, Buchwald SL. J. Am. Chem. Soc. 2002; 124: 14844
3b Antilla JC, Klapars A, Buchwald SL. J. Am. Chem. Soc. 2002; 124: 11684

4a Ma D, Cai Q, Zhang H. Org. Lett. 2003; 5: 2453
4b Ma D, Cai Q. Acc. Chem. Res. 2008; 41: 1450

5 Enguehard C, Allouchi H, Gueiffier A, Buchwald SL. J. Org. Chem. 2003; 68: 4367

6a Gujadhur RK, Bates CG, Venkataraman D. Org. Lett. 2001; 3: 4315
6b Han C, Shen R, Su S, Porco JA. Org. Lett. 2003; 6: 27

7a Shafir A, Buchwald SL. J. Am. Chem. Soc. 2006; 128: 8742
7b Fagan PJ, Hauptman E, Shapiro R, Casalnuovo A. J. Am. Chem. Soc. 2000; 122: 5043

8 Fisher MH, Lusi A. J. Med. Chem. 1972; 15: 982
9 Gueiffier A, Mavel S, Lhassani M, Elhakmaoui A, Snoeck R, Andrei G, Chavignon O, Teulade J.-C, Witvrouw M, Balzarini J, De Clercq E, Chapat J.-P. J. Med. Chem. 1998; 41: 5108
10 Ulloora S, Shabaraya R, Adhikari AV. Bioorg. Med. Chem. Lett. 2013; 23: 3368
11 Baviskar AT, Madaan C, Preet R, Mohapatra P, Jain V, Agarwal A, Guchhait SK, Kundu CN, Banerjee UC, Bharatam PV. J. Med. Chem. 2011; 54: 5013
12 Kaminski JJ, Bristol JA, Puchalski C, Lovey RG, Elliott AJ, Guzik H, Solomon DM, Conn DJ, Domalski MS. J. Med. Chem. 1985; 28: 876
13 Almirante L, Polo L, Mugnaini A, Provinciali E, Rugarli P, Biancotti A, Gamba A, Murmann W. J. Med. Chem. 1965; 8: 305
14 Ismail MA, Brun R, Wenzler T, Tanious FA, Wilson WD, Boykin DW. J. Med. Chem. 2004; 47: 3658
15 Chaouni-Benabdallah A, Galtier C, Allouchi H, Kherbeche A, Debouzy J.-C, Teulade J.-C, Chavignon O, Witvrouw M, Pannecouque C, Balzarini J, De Clercq E, Enguehard C, Gueiffier A. Arch. Pharm. 2001; 334: 224

16a Pericherla K, Khungar B, Kumar A. Tetrahedron Lett. 2012; 53: 1253
16b Pericherla K, Khedar P, Khungar B, Kumar A. Chem. Commun. 2013; 49: 2924
16c Khedar P, Pericherla K, Kumar A. Synlett 2012; 23: 2609

17 Sun M, Wu H, Zheng J, Bao W. Adv. Synth. Catal. 2012; 354: 835
18 Sperotto E, van Klink GP. M, van Koten G, de Vries JG. Dalton Trans. 2010; 39: 10338

19a Hu Y.-Y, Hu J, Wang X.-C, Guo L.-N, Shu X.-Z, Niu Y.-N, Liang Y.-M. Tetrahedron 2010; 66: 80
19b Eglinton G, Galbraith AR. J. Chem. Soc. 1959; 889

20 General Procedure for the Synthesis of Compound 3 A round-bottom flask (10 mL) was charged with 2-(2-bromophenyl)imidazo[1,2-a]pyridine (1, 0.36 mmol), azole 2 (0.439 mmol), CuI (0.07 mmol), K₂CO₃ (0.732 mmol), and DMF (2.0 mL). The resulting solution was stirred at 150 °C in an oil bath for 2 h under nitrogen atmosphere. On completion, the reaction mass was filtered through Celite and washed with EtOAc. The filtrate was washed with H₂O, dried over anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was purified by column chromatography (EtOAc–hexane, 2:3) to obtain the product 3.
21 General Procedure for the Synthesis of Compound 6 A round-bottom flask (10 mL) was charged with 2-(2-bromophenyl)imidazo[1,2-a]pyridine (1, 0.36 mmol), sodium azide (4, 0.439 mmol), phenylacetylene (5a, 0.439 mmol), CuCl₂·2H₂O (0.073 mmol), K₂CO₃ (0.732 mmol), and DMF (2.0 mL). The resulting solution was stirred at 100 °C in an oil bath for 3 h. On completion, the reaction mass was filtered through Celite and washed with EtOAc. The filtrate was washed with H₂O, dried over anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was purified by column chromatography (EtOAc–hexane, 2:3) to obtain product 6.
22 Spectroscopic Data of Selected Compounds 2-[2-(1H-Imidazol-1-yl)phenyl]H-imidazo[1,2-a]pyridine (3a) Yield 92%; colorless solid; mp 149–151 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.42 (dd, J = 7.9, 1.4 Hz, 1 H), 7.89 (dt, J = 6.8, 1.1 Hz, 1 H), 7.65–7.55 (m, 3 H), 7.44 (td, J = 7.6, 1.5 Hz, 1 H), 7.34 (dd, J = 7.8, 1.2 Hz, 1 H), 7.29 (s, 1 H), 7.18–7.14 (m, 1 H), 7.06 (s, 1 H), 6.73 (td, J = 6.8, 1.1 Hz, 1 H), 6.29 (s, 1 H). ¹³C NMR (126 MHz, CDCl₃): δ = 144.86, 140.10, 137.36, 134.31, 131.38, 129.95, 129.78, 129.67, 128.37, 127.71, 125.82, 125.06, 120.48, 117.43, 112.53, 109.70. HRMS: m/z calcd for C₁₆H₁₃N₄ ⁺: 261.1135; found: 261.1119 [M + H]⁺. 2-[2-(4-Methyl-1H-imidazol-1-yl)phenyl]H-imidazo [1,2-a]pyridine (3b) Yield 90%; colorless; mp 174–177 °C. ¹H NMR (300 MHz, CDCl₃): δ = 8.41 (dd, J = 7.9, 1.4 Hz, 1 H), 7.90 (dt, J = 6.8, 1.0 Hz, 1 H), 7.62–7.52 (m, 2 H), 7.47 (s, 1 H), 7.40 (td, J = 7.6, 1.5 Hz, 1 H), 7.32–7.26 (m, 1 H), 7.18–7.11 (m, 1 H), 6.76 (s, 1 H), 6.72 (td, J = 6.8, 1.1 Hz, 1 H), 6.40 (s, 1 H), 2.34 (s, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ = 144.82, 140.26, 138.83, 136.50, 134.55, 131.26, 129.88, 129.43, 128.30, 127.79, 125.84, 124.96, 117.43, 116.77, 112.46, 109.88, 13.76. HRMS: m/z calcd for C₁₇H₁₅N₄ ⁺: 275.1291; found: 275.1278 [M + H]⁺. 2-[2-(4-Phenyl-1H-1,2,3-triazol-1-yl)phenyl]H-imidazo[1,2-a]pyridine (6a) Yield 76%; off-white solid; mp 189–192 °C. ¹H NMR (300 MHz, DMSO-d ₆): δ = 8.89 (s, 1 H), 8.43 (d, J = 6.8 Hz, 1 H), 8.29 (d, J = 7.8 Hz, 1 H), 7.93 (d, J = 7.3 Hz, 2 H), 7.79–7.69 (m, 1 H), 7.59 (d, J = 3.1 Hz, 2 H), 7.51 (d, J = 4.8 Hz, 1 H), 7.46 (d, J = 7.7 Hz, 2 H), 7.36 (t, J = 7.3 Hz, 1 H), 7.27–7.15 (m, 1 H), 6.93 (s, 1 H), 6.80 (t, J = 6.7 Hz, 1 H). ¹³C NMR (75 MHz, DMSO-d ₆): δ = 147.98, 145.06, 140.34, 134.62, 131.26, 130.65, 130.56, 130.40, 128.86, 128.44, 128.29, 127.47, 126.15, 125.84, 125.00, 122.05, 117.55, 112.53, 110.39. HRMS: m/z calcd for C₂₁H₁₆N₅ ⁺: 338.1400; found: 338.1405 [M + H]⁺.

Zusatzmaterial

Supporting Information